Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus

NCT07319286 · Enrolling by invitation

Last updated 2026-05-28

This clinical trial is testing whether a medication called a GLP-1 receptor agonist can help reduce menstrual irregularities in adolescent girls with type 1 diabetes.

Status Enrolling by invitation Only people invited by the researchers can join.

Phase Phase1, Phase2

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 50 people Planned (estimated).

Who can join Ages 12–18 · all sexes

Timeline Started 2025-08 · est. completion 2026-08

Where 2 sites · Egypt

What this study is testing ClinicalTrials.gov NCT07319286 ↗

Description as written by the study sponsor.

The aim of this study is to measure the frequency of menstrual irregularities among adolescent females with Type 1 diabetes mellitus and to assess the therapeutic effect of glucagon-like peptide-1 receptor agonist on menstrual irregularities in adolescent females with Type 1 diabetes mellitus .

Treatments tested

Dulaglutide Drug

All studied patients with T1DM with poor glycemic control will be screened for menstrual irregularities based upon detailed history Taking, those who were found to have menstrual irregularities will be subdivided into 2 groups: * Group 1: will receive additional dulaglutide at a dose escalating from o.75 to 1.5 mg /week for 12 weeks to the conventional insulin therapy. * Group 2: will only receive conventional insulin therapy.

Main thing measured	Frequency of Self-Reported Menstrual Irregularities
Sponsor	Ain Shams University
Conditions studied	Menstrual Irregularities, Type1 Diabetes Mellitus, Glucagon-Like Peptide-1 Receptor Agonists, Female Reproductive Health
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07319286 ↗